Foundation Medicine Inc (NASDAQ:FMI) SVP Robert W. Hesslein sold 1,864 shares of Foundation Medicine stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $64.00, for a total value of $119,296.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Foundation Medicine Inc (FMI) traded down $1.60 during midday trading on Friday, reaching $67.10. The company had a trading volume of 285,542 shares, compared to its average volume of 376,393. The company has a current ratio of 2.24, a quick ratio of 2.03 and a debt-to-equity ratio of 0.47. Foundation Medicine Inc has a one year low of $17.50 and a one year high of $74.30. The stock has a market cap of $2,430.00, a PE ratio of -15.01 and a beta of -0.01.
Foundation Medicine (NASDAQ:FMI) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.90) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.06) by $0.16. The company had revenue of $42.66 million for the quarter, compared to analysts’ expectations of $37.99 million. Foundation Medicine had a negative return on equity of 143.18% and a negative net margin of 119.69%. The firm’s revenue was up 45.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.90) EPS. sell-side analysts predict that Foundation Medicine Inc will post -4.44 earnings per share for the current fiscal year.
FMI has been the topic of a number of research analyst reports. Zacks Investment Research raised Foundation Medicine from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a report on Monday, November 6th. BidaskClub raised Foundation Medicine from a “hold” rating to a “buy” rating in a report on Tuesday, December 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $45.33.
Institutional investors and hedge funds have recently modified their holdings of the company. Fiduciary Trust Co. purchased a new stake in shares of Foundation Medicine during the 2nd quarter worth approximately $119,000. Legal & General Group Plc raised its holdings in shares of Foundation Medicine by 8.6% during the 2nd quarter. Legal & General Group Plc now owns 3,442 shares of the company’s stock worth $138,000 after acquiring an additional 274 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Foundation Medicine by 36.6% during the 3rd quarter. SG Americas Securities LLC now owns 6,481 shares of the company’s stock worth $261,000 after acquiring an additional 1,736 shares in the last quarter. Voya Investment Management LLC purchased a new stake in shares of Foundation Medicine during the 2nd quarter worth approximately $262,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Foundation Medicine by 419.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,578 shares of the company’s stock worth $385,000 after acquiring an additional 7,735 shares in the last quarter. 32.68% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/13/foundation-medicine-inc-fmi-svp-sells-119296-00-in-stock.html.
About Foundation Medicine
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.